Navigation Links
Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer

For patients with high-risk breast cancer treated with radical mastectomy and adjuvant chemotherapy, the addition of radiation therapy leads to better survival outcomes with few long-term toxic effects, according to a 20-year follow-up of a randomized trial, which appears in the January 19 issue of the Journal of the National Cancer Institute.

The British Columbia randomized radiation therapy trial was designed to determine the effect on survival of the addition of locoregional radiation therapy (radiation to the lymph nodes and chest wall) to a course of chemotherapy after radical mastectomy in premenopausal women with lymph node–positive breast cancer. Between 1979 and 1986, 318 patients were randomly assigned to receive no radiation therapy or to receive radiation. A 15-year follow-up found that radiation therapy was associated with improved breast cancer survival but not with overall survival.

In this 20-year follow-up of the British Columbia trial, Joseph Ragaz, M.D., of McGill University Health Center in Montreal, and colleagues found that the chemotherapy and radiation regimen, compared with chemotherapy alone, was associated with improvement in all end points analyzed. This included a 32% reduction in breast cancer mortality and a 27% reduction in overall mortality compared with chemotherapy alone. In addition, long-term toxic effects, including cardiac deaths, were acceptable for both groups of patients.

"Our results, and those from other groups, confirm that in situations where residual disease remains, adjuvant chemotherapy alone in high-risk breast cancer patients is suboptimal and that the addition of locoregional radiation therapy is important to achieve the highest cure rate," the authors write.

In an editorial, Timothy Whelan, B.M., B.Ch., and Mark Levine, M.D., of the Juravinski Cancer Centre in Hamilton, Ontario, discuss the use of locoregional radiation therapy in breast cancer patients and note that fewer clinicians accept its use in moderate-risk patients. "Because uncertainties continue about the effectiveness of locoregional radiation therapy after mastectomy in moderate-risk patients, we strongly urge that a randomized controlled trial be mounted to resolve these uncertainties," they write.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Adding radiation decreases breast cancer recurrence
2. Duke Experiments Boost Radiations Cancer-Killing Effects
3. Radiation-killed bacteria vaccine induces broad immune response in mice
4. Radiation-armed robot rapidly destroys human lung tumors
5. Radiation after surgery doubles survival time for some lung cancer patients
6. Radiation therapy combo cures prostate cancer long-term
7. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
8. Gene Therapy For Parkinsons Disease Moves Forward In Animals
9. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
10. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
11. Discovery Promises Simpler Therapy for Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/30/2019)... ... October 29, 2019 , ... LGC ... SIEMENS ATELLICA® analyzers, Order Numbers 701sa & 704sa. The kits, in a human-urine ... and UUN. , Each VALIDATE® kit, liquid, ready-to-use, and prepared using the CLSI ...
(Date:10/29/2019)... ... October 29, 2019 , ... Fujirebio Diagnostics, Inc., a ... (FDA) clearance of the company’s Lumipulse® G whole PTH Assay for testing on ... by the parathyroid glands; which are four small glands located behind the thyroid ...
(Date:10/26/2019)... ... October 23, 2019 , ... ... bioceramic nanotube surface that demonstrated the FDA requirements for nanotechnology. , “We ... nanotechnology. This nanotechnology plays an important role in achieving Nanovis’ goal to reduce ...
Breaking Biology News(10 mins):
(Date:10/17/2019)... Kan. (PRWEB) , ... October 15, 2019 , ... ... 23andMe, a leader among services that offer DNA Testing for health and/or genealogy ... popular. Everywhere you look, it seems that people want to know more about ...
(Date:10/10/2019)... ... ... R3 Stem Cell announces it has added an exosome presentation to its upcoming ... spots still open. , The speaker, Dr. Ian White PhD, is a world renowned ... and Dartmouth. He currently serves as the Chief Scientific Officer at IMAC Regeneration Centers ...
(Date:10/3/2019)... ... October 01, 2019 , ... Today Cereset®, the only ... midway point of its randomized research trial for individuals with persisting symptoms following ... efficacy of a non-invasive technology which compares tones delivered to a subject’s brain ...
(Date:10/3/2019)... KITCHENER, Ontario (PRWEB) , ... October 02, 2019 ... ... protein sequencing using mass spectrometry, is pleased to announce that it has moved ... mass spectrometers among other analytical instruments, the new facility demonstrates the company's continuous ...
Breaking Biology Technology: